"Latigo Secures $135M for Non-Opioid Pain Medicine, Chasing Vertex Success"
Latigo Biotherapeutics, a non-opioid drug developer, has emerged with a $135 million Series A funding after years of development, targeting the same Nav1.8 as Vertex Pharmaceuticals. The company aims to address pain management without the risk of addiction by focusing on the peripheral nervous system.